Maze Therapeutics said its phase 2 program for MZE829, an oral dual-mechanism APOL1 inhibitor, achieved a clinically meaningful mean reduction in urine protein levels in APOL1-mediated kidney disease. In the Horizon study, Maze reported an average 35.6% reduction in proteinuria at week 12, with stronger results in focal segmental glomerulosclerosis cohorts. While shares fell sharply after the topline update, Maze confirmed it will continue enrollment and plans regulator discussions to advance MZE829 into a pivotal trial. The company emphasized that there are no approved therapies specifically targeting AMKD, leaving a clear competitive opening for a genetically driven intervention. Analyst notes in coverage framed the protein reduction as above an accepted benchmark and suggested the profile could be approvable depending on confirmatory study design and endpoint strategy.